Active Thoracic Compromised Distal LANding in TEvar
Launched by FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS · Mar 15, 2025
Trial Information
Current as of April 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring a treatment for patients with specific types of thoracic aortic aneurysms, which are bulges in the aorta located in the chest area. The focus is on improving the outcomes for patients whose aorta has a compromised area where a stent (a small mesh tube) is placed. Researchers are examining different types of stents to see which ones work best in these challenging cases. This is important because poor placement of stents can lead to serious complications, such as leaks or movement of the stent, which may worsen the condition of the aorta.
To participate in this study, patients should be between the ages of 65 and 74 and have a descending thoracic aortic aneurysm that is larger than 55 millimeters or growing quickly. Additionally, they must show certain features that indicate a complex aortic shape. However, patients in emergency situations or those with specific conditions like aortic dissection—where the layers of the aorta tear—won’t be eligible. If someone qualifies for the trial, they can expect to receive one of the different stent types and will be monitored closely to see how well it works.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with descending thoracic aortic aneurysms (DTAAs) with a maximal aortic diameter \> 55mm or rapid growth (\>10mm / year).
- • Patients presenting with at least 2 cognizable features related to an adverse aortic morphology will be considered for inclusion. The following features will be evaluated for the inclusion: distal LZ length ≤25-mm, distal LZ diameter ≥38-mm, LZ conical morphology, distal descending thoracic aorta angulation ≤116° or tortuosity index ≥1.4
- Exclusion Criteria:
- • Emergency setting, including hemodynamic instability at time of enrollment
- • Patients with aortic dissection pathology
About Fondazione Policlinico Universitario Agostino Gemelli Irccs
Fondazione Policlinico Universitario Agostino Gemelli IRCCS is a leading research and healthcare institution based in Rome, Italy, renowned for its commitment to advancing medical science and improving patient care. As a prominent academic medical center affiliated with the Catholic University of the Sacred Heart, it integrates clinical practice, education, and research, fostering innovation in various fields of medicine. The foundation conducts a wide range of clinical trials aimed at developing new therapies and enhancing treatment protocols, with a focus on translational research that bridges the gap between laboratory discoveries and patient care. Its multidisciplinary approach and dedication to high ethical standards position it as a key player in the landscape of clinical research and healthcare improvement in Italy and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Roma, Rm, Italy
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported